A Promising Paradigm Shift in Cancer Treatment with FGFR Inhibitors

被引:1
|
作者
Mehra, Anuradha [1 ]
Sangwan, Rekha [1 ]
机构
[1] Lovely Profess Univ, Sch Pharmaceut Sci, Dept Pharmaceut Chem, Jalandhar Delhi GT Rd NH 1, Phagwara 144411, Punjab, India
关键词
FGFR; anticancer; SAR; potency; heterocyclic; angiogenesis; FIBROBLAST-GROWTH-FACTOR; FACTOR RECEPTOR FAMILY; BIOLOGICAL EVALUATION; KINASE INHIBITOR; CH5183284/DEBIO; 1347; SELECTIVE INHIBITOR; PHASE-I; DESIGN; POTENT; DISCOVERY;
D O I
10.2174/0118715206318833240819031953
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
FGFR have been demonstrated to perform a crucial role in biological processes but their over-expression has been perceived as the operator component in the occurrence and progression of different types of carcinoma. Out of all the interest around cancer, FGFR inhibitors have assembled pace over the past few years. Therefore, FGFR inhibitors are one of the main fundamental tools to reverse drug resistance, tumor growth, and angiogenesis. Currently, many FGFR inhibitors are under the development stage or have been developed. Due to great demand and hotspots, different pharmacophores were approached to access structurally diverse FGFR inhibitors. Here, we have selected to present several representative examples such as Naphthyl, Pyrimidine, Pyridazine, Indole, and Quinoline derivatives that illustrate the diversity and advances of FGFR inhibitors in medicinal chemistry. This review focuses on the SAR study of FGFR inhibitors last five years which will be a great future scope that influences the medicinal chemist to work towards more achievements in this area.
引用
收藏
页码:2 / 23
页数:22
相关论文
共 50 条
  • [41] Personalized medicine: A paradigm shift towards promising health care
    Annadurai, Kalaivani
    Danasekaran, Raja
    Mani, Geetha
    JOURNAL OF PHARMACY AND BIOALLIED SCIENCES, 2016, 8 (01): : 77 - U86
  • [42] Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer
    Heather Katz
    Emnet Wassie
    Mohamed Alsharedi
    Medical Oncology, 2017, 34
  • [43] Exosomes in stroke management: A promising paradigm shift in stroke therapy
    Bo Wang
    Pinzhen Chen
    Wenyan Li
    Zhi Chen
    Neural Regeneration Research, 2026, 21 (01) : 6 - 22
  • [44] SGLT2 inhibitors in cancer patients: a paradigm shift in cardio-oncology?
    Cautela, Jennifer
    Alexandre, Joachim
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2025,
  • [45] Paradigm shift in the treatment of head and neck cancer: The role of neoadjuvant chemotherapy
    Posner, MR
    ONCOLOGIST, 2005, 10 : 11 - 19
  • [46] Preoperative radiotherapy: A paradigm shift in the treatment of breast cancer? A review of literature
    Corradini, Stefanie
    Krug, David
    Meattini, Icro
    Matuschek, Christiane
    Boelke, Edwin
    Francolini, Giulio
    Baumann, Rene
    Figlia, Vanessa
    Pazos, Montserrat
    Tonetto, Fabrizio
    Trovo, Marco
    Mazzola, Rosario
    Alongi, Filippo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 141 : 102 - 111
  • [47] National adoption of neoadjuvant chemotherapy: paradigm shift in the treatment of pancreatic cancer
    Nassour, Ibrahim
    Parrish, Austin
    Baptist, Lucy
    Voskamp, Sarah
    Handoo, Komal
    Rogers, Sherise
    Fabregas, Jesus
    George, Thomas
    Hitchcock, Kathryn
    Paniccia, Alessandro
    Hughes, Steven
    HPB, 2023, 25 (11) : 1323 - 1328
  • [48] Can Salvage Surgery Cause a Paradigm Shift in Lung Cancer Treatment?
    Shimizu, Kimihiro
    ANNALS OF THORACIC SURGERY, 2022, 114 (04): : 1518 - 1519
  • [49] Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer
    Facchinetti, Francesco
    Hollebecque, Antoine
    Braye, Floriane
    Vasseur, Damien
    Pradat, Yoann
    Bahleda, Rastislav
    Pobel, Cedric
    Bigot, Ludovic
    Deas, Olivier
    Florez-Arango, Juan-David
    Guaitoli, Giorgia
    Mizuta, Hayato
    Combarel, David
    Tselikas, Lambros
    Michiels, Stefan
    Nikolaev, Sergey
    Scoazec, Jean-Yves
    Ponce-Aix, Santiago
    Besse, Benjamin
    Olaussen, Ken A.
    Loriot, Yohann
    Friboulet, Luc
    CANCER RESEARCH, 2023, 83 (07)
  • [50] Resistance to Selective FGFR Inhibitors in FGFR- Driven Urothelial Cancer
    Facchinetti, Francesco
    Hollebecque, Antoine
    Braye, Floriane
    Vasseur, Damien
    Pradat, Yoann
    Bahleda, Rastislav
    Pobel, Cedric
    Bigot, Ludovic
    Deas, Olivier
    Arango, Juan DavidFlorez
    Guaitoli, Giorgia
    Mizuta, Hayato
    Combarel, David
    Tselikas, Lambros
    Michiels, Stefan
    Nikolaev, Sergey I.
    Scoazec, Jean-Yves
    Ponce-Aix, Santiago
    Besse, Benjamin
    Olaussen, Ken A.
    Loriot, Yohann
    Friboulet, Luc
    CANCER DISCOVERY, 2023, 13 (09) : 1998 - 2011